PLoS Biol. 2022 Aug 9;20(8):e3001721. doi: 10.1371/journal.pbio.3001721. eCollection 2022 Aug.
The Comprehensive Resistance Prediction for Tuberculosis: an International Consortium (CRyPTIC) presents here a data compendium of 12,289 Mycobacterium tuberculosis global clinical isolates, all of which have undergone whole-genome sequencing and have had their minimum inhibitory concentrations to 13 antitubercular drugs measured in a single assay. It is the largest matched phenotypic and genotypic dataset for M. tuberculosis to date. Here, we provide a summary detailing the breadth of data collected, along with a description of how the isolates were selected, collected, and uniformly processed in CRyPTIC partner laboratories across 23 countries. The compendium contains 6,814 isolates resistant to at least 1 drug, including 2,129 samples that fully satisfy the clinical definitions of rifampicin resistant (RR), multidrug resistant (MDR), pre-extensively drug resistant (pre-XDR), or extensively drug resistant (XDR). The data are enriched for rare resistance-associated variants, and the current limits of genotypic prediction of resistance status (sensitive/resistant) are presented by using a genetic mutation catalogue, along with the presence of suspected resistance-conferring mutations for isolates resistant to the newly introduced drugs bedaquiline, clofazimine, delamanid, and linezolid. Finally, a case study of rifampicin monoresistance demonstrates how this compendium could be used to advance our genetic understanding of rare resistance phenotypes. The data compendium is fully open source and it is hoped that it will facilitate and inspire future research for years to come.
《结核病综合耐药预测:国际联盟(CRyPTIC)》在此呈现了一份包含 12289 株全球结核分枝杆菌临床分离株的综合数据摘要,这些分离株均进行了全基因组测序,并在单一检测中测量了其对 13 种抗结核药物的最低抑菌浓度。这是迄今为止最大的结核分枝杆菌表型和基因型匹配数据集。在这里,我们提供了一份详细总结,其中包括所收集数据的广度,并描述了如何在 CRyPTIC 合作伙伴实验室中从 23 个国家/地区选择、收集和统一处理这些分离株。该摘要包含了至少对 1 种药物耐药的 6814 株分离株,其中包括 2129 个完全符合利福平耐药(RR)、耐多药(MDR)、预广泛耐药(pre-XDR)或广泛耐药(XDR)临床定义的样本。该数据丰富了罕见耐药相关变异体,并且还通过使用基因突变目录以及对新引入的贝达喹啉、氯法齐明、德拉马尼和利奈唑胺耐药的分离株中可疑耐药相关突变的存在,展示了当前基因型预测耐药状态(敏感/耐药)的局限性。最后,对利福平单耐药的案例研究表明,该摘要如何可用于推进我们对罕见耐药表型的遗传理解。该数据摘要完全开源,希望它将在未来几年内促进和激发研究。